Business Wire

THALES

12.6.2019 07:02:08 CEST | Business Wire | Press release

Share
Gemalto Identity Management System to Empower the World’s Citizens with Secure and Unique Identities

Gemalto, a Thales company, is launching its Identity Management System (IDMS) that can help governments address the challenges posed by a world in which over one billion people have no official ID. Using the latest biometric capture and identity verification techniques, Gemalto’s solutions enable public authorities to empower citizens with a fully secured and trusted Foundational Identity. This system supports people identification and authentication so they can securely access online and offline services such as education or healthcare, and proves their right to participate in elections, apply for a passport or open a bank account. Users retain full control over their personal data, choosing how and when it is shared with service providers.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190611005462/en/

UN targets universal provision of ID by 2030

The staggering number of citizens rendered invisible to public agencies by the absence of an official ID includes one out of three children worldwide. Most international financial institutions are supporting Digital ID schemes in many countries over the next ten years. These initiatives are also backed by the UN, which has itself set the target of everyone on the planet having a legal identity by 20301 .

Mobile, biometric-based registration can reach remote and isolated areas

Gemalto’s IDMS provides authorities with a fully integrated, end-to-end solution which can adapt to existing identity schemes and orchestrate its interactions. The process starts with registration of a person and capture of their biometrics, with easy-to use mobile technology ensuring coverage can reach even the most remote regions. Registration is followed by entry onto a central database or civil registry and the creation of a unique individual identifier.

Reaping the benefits of Foundational ID

This Foundational Identity can provide the basis for issuance of digital and physical ID credentials, and subsequent registration with numerous different public bodies and services. All these processes can be verified beyond doubt using the individual’s biometrics and unique identifier. Gemalto’s approach also offers citizens outstanding protection, and assurance that their data will not be used for commercial gain.

Promoting inclusion, fighting fraud

For governments, a universal ID program facilitates accurate planning of public services, and comprehensive social inclusion strategies. Robust protection against the threat of fraud is also provided, as part of the digital ID platform to further boost efficiency, convenience and adoption of eServices. The Foundational Identity also eliminates the need for individual bodies, such as those responsible for health and welfare, to continually repeat enrollment procedures.

“A unique legal ID is a basic human right that can unlock access to many more – including education, welfare and participation in the democratic process,” said Frédéric Trojani, senior vice president Identity and Biometric Solutions for Thales . “Our Identity Management System leverages unrivalled experience in delivering Digital Identity solutions that empower citizens, defend their personal data, and ensure unhindered access to the rights and services.”

Note to editors

Gemalto’s solutions are at the heart of modern life, from payment to enterprise security and the internet of things. Gemalto’s technologies and services authenticate people, transactions and objects, encrypt data and create value for software – enabling businesses and governments to deliver secure digital services for billions of individuals and things.

About Thales

The people we all rely on to make the world go round – they rely on Thales. Our customers come to us with big ambitions: to make life better, to keep us safer. Combining a unique diversity of expertise, talents and cultures, our architects design and deliver extraordinary high technology solutions. Solutions that make tomorrow possible, today. From the bottom of the oceans to the depth of space and cyberspace, we help our customers think smarter and act faster - mastering ever greater complexity and every decisive moment along the way. With 80,000 employees in 68 countries, Thales reported sales of €19 billion in 2018.

PLEASE VISIT

Thales Group
Digital Security
Download HD photos

1 UN Sustainable Development Goal (SDG) 16.9

Contact:

PRESS Thales, Media Relations Security Constance Arnoux +33 (0)6 44 12 16 35 constance.arnoux@thalesgroup.com

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release

Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release

News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi

Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo

IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release

Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr

BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release

Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye